Concentration of natriuretic peptides in patients suffering from idiopathic arterial hypertension and left ventricular diastolic dysfunction confirmed by echocardiography

Clinical and Experimental Hypertension

Volumn 34, Issue 7, 2012, Pages 530-540

  Irzmański, Robert ^a   Pawlicki, Lucjan ^a   Charłusz, Magdalena ^a   Kowalski, Jan ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Echocardiography idiopathic hypertension; Heart failure; Left ventricular diastolic dysfunction; Natriuretic peptides

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ATRIAL NATRIURETIC FACTOR; BRAIN NATRIURETIC PEPTIDE; CREATININE; NATRIURETIC FACTOR; POTASSIUM ION; SODIUM ION; UREA;

ADULT; ARTICLE; BODY MASS; CHRONIC RESPIRATORY TRACT DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; DOPPLER ECHOGRAPHY; EARLY DIAGNOSIS; ECHOCARDIOGRAPHY; ESSENTIAL HYPERTENSION; FEMALE; HEART ARRHYTHMIA; HEART ATRIUM CONTRACTION; HEART EJECTION FRACTION; HEART FAILURE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HEART VENTRICLE HYPERTROPHY; HUMAN; LEFT VENTRICULAR DIASTOLIC DYSFUNCTION; MALE; PULMONARY VEIN; RELAXATION TIME; SYSTOLIC BLOOD PRESSURE; VEIN BLOOD FLOW;

ATRIAL NATRIURETIC FACTOR; ECHOCARDIOGRAPHY, DOPPLER; FEMALE; HEART ATRIA; HEART VENTRICLES; HUMANS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; MIDDLE AGED; NATRIURETIC PEPTIDES; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84870436806     PISSN: 10641963     EISSN: 15256006     Source Type: Journal    
DOI: 10.3109/10641963.2012.702831     Document Type: Article

References (47)

1. Mayet J, Shabi M, Pounter N. Left ventricular diastolic function in hypertension: a four-year follow-up study. Int J Cardiol 1995; 50:181-188.
2. Phillips RA, Goldman ME, Ardeijan M. Determinants of abnormal left ventricular filling in early hypertension. J AmColl Cardiol 1989; 14:979-985.
3. Krumholz HM, Larson M, Levy D. Sex differences in cardiac adaptation to isolated systolic hypertension. Am J Cardiol 1993; 72:310-315.
4. Klingbeil AU, Schneider M, Martus P, et al. A meta-analysis of the effects of treatment on left ventricular mass in essential hypertension. Am J Med 2003; 115:41-46.
5. Tecce MA, Pennington JA, Segal BL, Jessup ML. Heart failure clinical implications of systolic and diastolic dysfunction. Geriatrics 1999; 54:24-28, 31-33.
6. Brutsaert DL, Sys SU. Diastolic dysfunction in heart failure. J Card Fail 1997; 3:225-242.
7. Jessup M, Brozena S. Heart failure. N Engl J Med 2003; 348:2007-2018.
8. Vasan RS, Levy D. Defining diastolic heart failure: a call for standardized diagnostic criteria. Circulation 2000; 101:2118-2121.
9. Levy D, Larson MG, Vasan RS, et al. The progression from hypertension to gongestive heart failure. J Am Med Assoc 1996; 275:1557-1762.
10. Fouad FM, Slominski JM, Tarazi RC. Left ventricular diastolic function in hypertension: relation to left ventricular mass and systolic function. J Am Coll Cardiol 1984; 3:1500-1506.
11. Lewartowski B. Układ renina-angiotensyna-aldosteron i jego rola w patologii serca. Kardiol Pol 1998; 49:20-26.
12. Weber KT. Fibrosis, a common pathway to organ failure: angiotensin II and tissue repair. Semin Nephrol 1997; 17:461-467.
13. Hobbs FDR, Davis RC, Roalfe AK, Kannel WB, Ho KK. Reliability of N-terminal pro-brain natriuretic peptide assay in diagnosis of heart failure: cohort study in representative and high risk community population. BMJ 2002; 324:1498-1500.
14. Landray MJ, Lehman R, Arnold I. Measuring brain natriuretic peptide in suspected left ventricular systolic dysfunction in general practice: observation study. BMJ 2000; 320:906-908.
15. Cowie MR, Stuther AD, Robb SD, Wood DA. Value of natriuretic peptides in assessment of patients with possible new heart failure in primary care. Lancet 1998; 350:1349-1351.
16. McDonagh TA, Robb SD, Murdoch DR. Biochemical detection of left-ventricular systolic dysfunction. Lancet 1998; 351:9-13.
17. Motwani JG, McAlfine H, Kennedy N, Struthers AD. Plasma BNP as an indicator for angiotensin-converting enzyme inhibition after myocardial infarction. Lancet 1993; 341:1109-1113.
18. Januszewicz A. The natriuretic peptides in hypertension. Curr Opin Cardiol 1995; 10(5):495-500.
19. Ellinor PT, Low AF, Patton KK, Shea MA, McRae CA. Discordant atrial natriuretic peptide and brain natriuretic peptide levels in lone atrial fibrillation. J Am Coll Cardiol 2005; 45:82-86.
20. Masuyama T, Lee JM, Yamamoto K, Tanouchi J, Hori M, Kamada T. Analysis of pulmonary venous flow velocity pattern in hypertensive hearts: its complementary value in the interpretation of mitral flow velocity patterns. Am Heart J 1992; 124:983-994.
21. Kasner M, Westermann D, Steendijk P, et al. Utility of Doppler echocardiography and tissue Doppler imaging in the estimation of diastolic function in heart failure with normal ejection fraction. A comparative Doppler-conductance catheterization study. Circulation 2007; 116:637-647.
22. Yu CM, Sanderson JE, Shum IOL, et al. Higher ANP and BNP levels are associated with the restrictive filling pattern. Eur Heart J 1996; 17:1694-1702.
23. Fruhwald FM, Fahleitner A, Watzinger N, et al. Natriuretic peptides in patients with diastolic dysfunction due to idiopatic dilated cardiomyopathy. Eur Heart J 1999; 20:1415-1423.
24. Lubien E, DeMaria A, Krishnaswamy P, et al. Utility of B-natriuretic peptide in detecting diastolic dysfunction. Comparison with Doppler velocity recordings. Circulation 2002; 105:595-601.
25. Fruhwald FM, Fahleitner A, Watzinger N, et al. N-terminal proatrial natriuretic peptide correlates with systolic dysfunction and left ventricular filling pattern in patients with idiopathic dilated cardiomyopathy. Heart 1999; 82:630-633.
26. Irzmanski RS. Peptydów natriuretycznych ANP, N-ANP i BNP, N-BNP w wybranych chorobach układu kra̧żenia. Ocena ich zależności z echokardiograficznymi wskaźnikami funkcji serca. Arch Med. Sci 2007; 3(1 suppl. 1):1-44.
27. ChienK,KnowltonK, Zhu K, Chien S. Regulation of gene expression during myocardial growth and hypertrophy:molecular studies of an adaptive physiologic process. FASEB J 1991; 5:3037-3046.
28. Langenickel T, Pagel I, Höhnel K, Dietz R, Willenbrock R. Differential regulation of cardiac ANP and BNP mRNA in different stages of experimental heart failure. Am J Physiol Heart Circ Physiol 2000; 278:H1500-H1506.
29. Yasumoto K, Takata M, Ueno H, Tomita S, Tomoda F, Inoue H. Relation of plasma brain and atrial natriuretic peptides to left ventricular geometric patterns in essential hypertension. Am J Hypertens 1999; 12:921-924.
30. Chobaniam AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure. The JNC 7 report. JAMA 2003; 289:2560-2572.
31. Devereux RB. Regression of left ventricular hypertrophy. How and why? J Am Med Assoc 1996; 275:1517-1518.
32. Li L, Shigematsu Y, Hamada M, Hidawa K. Relative wall thickness is an independent predictor of left ventricular systolic and diastolic dysfunctions in essential hypertension. Hypertens Res 2001; 24(5):439-499.
33. Appleton CHP, Galloway JM, Gonzales MS, Gaballa M, Basnight MA. Estimation of left ventricular filling pressures using twodimensional and Doppler echocardiography in adult patients with cardiac disease. Additional value of analyzing left atrial size, left atrial ejection fraction and difference in duration of pulmonary venous and mitral flow velocity at atrial contraction. J Am Coll Cardiol 1993; 22:1972-1982.
34. Appleton CHP, Jensen JL, Halte LK, Oh JK. Doppler evaluation of left and right ventricular diastolic function: a technical guide for obtaining optimal flow velocity recordings. J Am Soc Echocardiogr 1997; 10:271-291.
35. Devereux RB. Left ventricular geometry. Pathophysiology and prognosis. J Am Coll Cardiol 1995; 25:885-887.
36. Rosa EC, Moyses VA, Rivera I, et al. Left ventricular diastolic function in essential hypertensive patients. Influence of age and left ventricular geometry. Arq Bras Cardiol 2002; 78:472-477.
37. Nishikimi T, Yoshihara F, Morimoto A, et al. Relationship between left ventricular geometry and natriuretic peptide levels in essential hypertension. Hypertension 1996; 28:22-30.
38. Muscholl MW, Schunkert H, Muders F, et al. Neurohormonal activity and left ventricular geometry in patients with essential arterial hypertension. Am Heart J 1998; 135:58-66.
39. McKinsey TA, Nolson EN. Cardiac hypertrophy: sorting out the circuitry. Curr Opin Gen Dev 1999; 9:267-274.
40. Irzmanski R, Banach M, Piechota M, et al. BNP concentration in patients with mitral stenosis. Dependence on selected morphological parameters. Arch Med Sci 2006; 2(1):15-19.
41. Irzmanski R, Banach M, Piechota M, et al. Atrial, brain natriuretic peptide and endothelin-1 concentration in patients with idiopathic arterial hypertension. The dependence on the selected morphological parameters. Clin Exp Hypertens 2007; 29:149-164.
42. Trushinsky ZK, Dovgalyuk V, Skritskaya O. Correlation between left ventricular hypertrophy and diastolic dysfunction in arterial hypertension. Ter Arch 2003; 75:57-59.
43. Edvardsen T, Rosen BD, Pan L, et al. Regional diastolic dysfunction in individuals with left ventricular hypertrophy by tagged magnetic resonance imaging - the Multi-Ethnic Study of Atherosclerosis (MESA). Am Heart J 2006; 151:109-114.
44. Weber T. Fibrosis and hypertensive heart disease. Curr Opin Caardiol 2000; 15:264-272.
45. Dardas PS, Filippatos GS, Tsikaderis DD, et al. Noninvasive indexes of left atrial diastolic function in hypertrophic cardiomyopathy. J Am Soc Echocardiogr 2000; 13:809-817.
46. Kosmala W, Przewłocka-Kosmala M, Mazurek W. Abnormalities of pulmonary venous patients with lone atrial fibrillation. Europace 2006; 8:102-106.
47. Redfield MM, Jacobsen SJ, Burnet JC, et al. Diastolic dysfunction was predictive of all cause mortality. J Am Med Assoc 2003; 289:194-202.